Outlook Therapeutics files CMS code application and Outlook Therapeutics stock trades at EUR 0.53

Published on 10/05/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The CMS filing advances reimbursement ahead of a 2026 U.S. launch. Outlook Therapeutics stock costs EUR 0.53 on October 5, 2026 after EUR 0.53.

OTLK, US69012T3059, Illustration mit AI erstellt.

Outlook Therapeutics (ISIN US69012T3059) was trading at EUR 0.53 at Lang & Schwarz on October 5, 2026 at 7:13 p.m. CEST, unchanged from the prior close of EUR 0.53. On October 1, 2026, the company filed a CMS code application for LYTENAVA, according to Finanznachrichten.

CMS code targets reimbursement

The application asks the Centers for Medicare & Medicaid Services for a permanent, product-specific Healthcare Common Procedure Coding System Level II code for LYTENAVA, the company said in the October 1 release carried by Finanznachrichten. The filing is designed to support reimbursement and simplify billing for physician-administered treatment, giving the commercial launch a market-access component beyond regulatory approval.

CMS reviews applications for drugs and biological products on a quarterly basis. The release also states that the application itself is separate from coverage and payment decisions, making reimbursement execution a key commercial milestone for Outlook Therapeutics.

Commercial launch carries a date

Outlook Therapeutics said on October 1, 2026, that it remains on track for a U.S. commercial launch of LYTENAVA before the end of 2026. The product is the company's lead ophthalmic therapy for neovascular, or wet, age-related macular degeneration.

The investor-relations profile describes Outlook Therapeutics as a biopharmaceutical company focused on commercializing LYTENAVA and expanding ophthalmic bevacizumab access; the company also identifies a strategic commercialization agreement with Cencora for logistics, distribution and related support, according to Outlook Therapeutics.

Market value stays measurable

OTLK's market capitalization was USD 109.8 million as of October 5, 2026, while its 52-week range was USD 0.16 to USD 2.54. Trading volume reached 2,342,484 shares against an average volume of 13,629,053 shares, putting the session activity at 17.18 percent of that average.

That market profile leaves the reimbursement filing and the planned 2026 launch as the concrete milestones investors can track. Outlook Therapeutics is classified as a healthcare biotechnology company, and its Nasdaq listing and OTLK ticker are confirmed by Stock Analysis.

OTLK trades flat after hours

Outlook Therapeutics was trading at EUR 0.53 at Lang & Schwarz on October 5, 2026 at 7:13 p.m. CEST, unchanged at plus 0.00 percent versus the Lang & Schwarz prior close of EUR 0.53. The primary listing is Nasdaq in USD.